Thrombus on the Tricuspid Valve in a Patient With Primary Antiphospholipid Syndrome After Implantation of an Inferior Vena Cava Filter

Mio Ebato, MD; Hitomi Kitai, BE*; Hideko Kumakura, BE*; Yoshiko Nakamura, MD; Nobuyuki Shimizu, MD**; Youichi Takeyama, MD**

A 62-year-old woman with a history of pulmonary embolism and primary antiphospholipid syndrome (PAPS) with positivity for lupus anticoagulant was admitted to hospital with shortness of breath. A filter had been implanted in her inferior vena cava (IVC) 5 years previously. Emergency echocardiography revealed a lobulated, mobile echogenic mass on the tricuspid valve, and on pulmonary perfusion scintigraphy several apparently new defects were noted. Fibrinolytic therapy improved her symptoms and the pulmonary perfusion, then intravenous heparinization was continued for a further week. Repeat echocardiography performed on the 7th day of the admission showed complete disappearance of the mass, which was retrospectively diagnosed as a thrombus based on its resolution with fibrinolytic and anticoagulant therapies. (Circ J 2002; 66: 425–427)

Key Words: Inferior vena cava; Primary antiphospholipid syndrome; Thrombus; Tricuspid valve

Antiphospholipid syndrome (APS) is a combination of the clinical symptoms of arterial and venous thromboembolism and the presence of autoantibodies such as antiphospholipid [2] GPI antibody, the lupus anticoagulant and the antibodies responsible for the false-positive serologic test result for syphilis. Primary APS (PAPS) is defined by the presence of these antibodies and thromboembolic phenomena without systemic lupus erythematosus (SLE) and other disease processes. Intracardiac thrombi have been reported1–7 but involvement of the tricuspid valve is extremely rare. We report a case of PAPS with a lobulated thrombus on the tricuspid valve, which formed after implantation of a filter in the inferior vena cava (IVC) and resolved with fibrinolytic therapy.

Case Report

A 62-year-old woman was admitted with progressive shortness of breath and tachypnea. The patient’s medical history included a 15-year history of bronchial asthma, and a pulmonary embolism caused by a deep vein thrombus 5 years previously. At that time, computed tomography (CT) revealed a large thrombus in the main pulmonary artery, which dissolved with intravenous administration of tissue plasminogen activator. Although several perfusion–ventilation mismatch areas remained on the pulmonary perfusion scan after the therapy (segment 6 on the left, segment 8 on the right), she was discharged with no symptoms after the implantation of an IVC filter. Further evaluation during that admission led to the diagnosis of PAPS with positivity for lupus anticoagulant. The anticardiolipin [2] GPI antibody level was less than 1.2 U/ml. Antinuclear antibodies were negative, and the activities of proteins C and S were normal, consistent with the diagnosis. She had no history of spontaneous abortion and had delivered normally with 3 pregnancies. After discharge, she was treated with warfarin with a target international normalized ratio (INR) of 2.0 at an outpatient clinic.

One year later, she was admitted to examine her pulmonary pressure and right heart pressure, which were found to be in the normal range. A repeat pulmonary perfusion scan showed no change. She continued to be positive for lupus anticoagulant at the second admission. Since then, she has been followed at an outpatient clinic and managed with warfarin bronchodilator and warfarin. However, the warfarin therapy was discontinued 10 months prior to her third admission.

On the third admission, she had an oxygen saturation of 89%, a respiratory rate of 28 breaths/min, and a 12-lead ECG that showed an inverted T wave in leads V1–3. Chest X-ray suggested dilatation of the right pulmonary artery. Laboratory tests revealed a white blood cell count of 12,500/mm³, hematocrit 41.7%, and platelet counts 124,000/mm³. Transthoracic echocardiography revealed a 1.7×1.8 cm, lobulated, isoechoic, highly mobile mass on the septal leaflet of the tricuspid valve (Fig 1). The right atrium and ventricle were dilated and mild tricuspid regurgitation was detected, with an estimated pulmonary artery systolic pressure of 65 mmHg. Her left heart valves were normal and there were no abnormalities in the left ventricular wall motion. Pulmonary perfusion scan revealed a new perfusion defect in the left upper lobe and global hypoperfusion of the right lobe in addition to the previously detected defects (Fig 2). Myxoma and nonbacterial vegetation were considered in the differential diagnosis of the mass and surgical removal.
of the mass was discussed. However, because of her rapidly worsening symptoms and their similarity to those of her previous admission, it was felt that immediate medical therapy was necessary. Tissue plasminogen activator (1,800,000 IU of Alteplase) was given intravenously and soon after, her symptoms began to resolve and her blood gas levels improved.

On the second day of admission, the oxygen saturation, which had improved to 97% after fibrinolytic therapy under oxygenation, decreased to 92% although she had no symptoms of hypoxemia. A repeat pulmonary perfusion scan showed new defects in the right lower lobe with improvement in the perfusion of the left upper lobe. Alteplase (1,200,000 IU) was again infused followed by intravenous heparinization. Later that day, echocardiography was performed and the mobile mass appeared to be smaller in size. Heparin infusion was continued for 6 days followed by warfarin as anticoagulant therapy.

On the seventh hospital day, repeat echocardiography demonstrated complete dissolution of the mass on the tricuspid valve (Fig 3) and the tricuspid regurgitation had also decreased to a trivial level with a peak speed normalized to 2.4 m/s. Pulmonary perfusion scan showed further improvements in the left upper and right lower lobes. Right heart catheterization performed 3 weeks after the admission demonstrated normal pulmonary artery pressure, right ventricular pressure and right atrial pressure. Fourteen
months later, she remains free of symptoms without any thromboembolic episodes while continuing warfarin with a target INR 2.0–2.5.

Discussion

The prevalence of valvular disease in PAPS has been reported to be between 35% and 75% in patients with APS. Tricuspid valve lesions have been reported in a few patients with APS. Sastry reported isolated tricuspid valve vegetation with severe tricuspid regurgitation in a patient with APS secondary to SLE and histopathologic examination of the excised valve showed diffuse, thickened leaflets with commissure fusion. The efficacy of anticoagulant therapy on vegetative lesions is controversial in patients with APS in some cases, on normal-functioning right and left ventricles. There have been few reports of thrombus on the tricuspid valve in patients with APS. Day et al reported a right atrial thrombus associated with APS, one of which was adherent to the edge of the anterior leaflet of the tricuspid valve.

In the present patient’s case, the mass shown by echocardiography was considered to be a thrombus because it dissolved upon fibrinolytic and anticoagulant therapy. Right heart entrapment of pulmonary emboli in-transit has been reported but considering the size of the thrombus in the presence of an IVC filter placed during a previous admission, the current thrombus may have formed in the right atrium and moved to the tricuspid valve or it may have formed directly on the ventricular side of the tricuspid valve.

In patients with APS, careful use of anticoagulant therapy is necessary to prevent high-risk recurrence attributable to antibody persistence and pulmonary embolization. There is a high risk of recurrence after discontinuation of oral anticoagulant therapy but the risk of reocclusion has been shown to be lower in patients with APS compared to the general population. Therefore, long-term anticoagulant therapy is thought to be necessary. The appropriate dose of warfarin in such patients is controversial. Lifelong treatment with oral anticoagulants with a target INR of 3.0 or more has been recommended, based on data from 3 retrospective studies but several recent reports have suggested that many patients with APS can be treated with conventional doses of warfarin. The risk of high-intensity anticoagulant therapy in patients with APS has also been reported. The present patient’s course has been uneventful for 14 months on a target INR of 2.0–2.5 after the most recent episode. Large-scale prospective studies will identify the optimal treatment for individual patients with APS.

References

10. Garcia-Torres R, Amigo MC, De la Rosa A, Maron A, Reyes PA. Large-scale prospective studies will identify the optimal treatment for individual patients with APS. Circulation Journal Vol.66, April 2002

427


Circulation Journal Vol.66, April 2002